Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 295

1.

Higher health care use before a clinically isolated syndrome with or without subsequent MS.

Marrie RA, Wijnands JMA, Kingwell E, Zhu F, Zhao Y, Ekuma O, Lu X, Evans C, Fisk JD, Tremlett H.

Mult Scler Relat Disord. 2019 Jul 2;35:42-49. doi: 10.1016/j.msard.2019.07.002. [Epub ahead of print]

PMID:
31319354
2.

Harnessing real-world data to inform treatment decisions in multiple sclerosis.

Hersh CM, Marrie RA.

Neurology. 2019 Jul 12. pii: 10.1212/WNL.0000000000007934. doi: 10.1212/WNL.0000000000007934. [Epub ahead of print] No abstract available.

PMID:
31300545
3.

Persistence of use of prescribed cannabinoid medicines in Manitoba, Canada: a population-based cohort study.

Alkabbani W, Marrie RA, Bugden S, Alessi-Severini S, Bolton JM, Daeninck P, Leong C.

Addiction. 2019 Jun 25. doi: 10.1111/add.14719. [Epub ahead of print]

PMID:
31240747
4.

High rates of health care utilization in pediatric multiple sclerosis: A Canadian population-based study.

Marrie RA, O'Mahony J, Maxwell CJ, Ling V, Yeh EA, Arnold DL, Bar-Or A, Banwell B; Canadian Pediatric Demyelinating Disease Network.

PLoS One. 2019 Jun 11;14(6):e0218215. doi: 10.1371/journal.pone.0218215. eCollection 2019.

5.

Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis.

Marrie RA, Dufault B, Tyry T, Cutter GR, Fox RJ, Salter A.

Mult Scler. 2019 Jun 4:1352458519852722. doi: 10.1177/1352458519852722. [Epub ahead of print]

PMID:
31161917
6.

Recognizing the diversity gap in multiple sclerosis.

Marrie RA.

Mult Scler. 2019 May 28:1352458519850070. doi: 10.1177/1352458519850070. [Epub ahead of print] No abstract available.

PMID:
31134835
7.

Adjusting for differential misclassification in matched case-control studies utilizing health administrative data.

Högg T, Zhao Y, Gustafson P, Petkau J, Fisk J, Marrie RA, Tremlett H.

Stat Med. 2019 Aug 30;38(19):3669-3681. doi: 10.1002/sim.8203. Epub 2019 May 21.

PMID:
31115088
8.

Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis.

Fitzgerald KC, Salter A, Tyry T, Fox RJ, Cutter G, Marrie RA.

Mult Scler. 2019 May 13:1352458519845836. doi: 10.1177/1352458519845836. [Epub ahead of print]

PMID:
31079537
9.

MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.

Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group.

Trials. 2019 May 9;20(1):263. doi: 10.1186/s13063-019-3346-z.

10.

The association of fatigue and social participation in multiple sclerosis as assessed using two different instruments.

Salter A, Fox RJ, Tyry T, Cutter G, Marrie RA.

Mult Scler Relat Disord. 2019 Jun;31:165-172. doi: 10.1016/j.msard.2019.04.014. Epub 2019 Apr 13.

PMID:
31063935
11.

Gender differences in information needs and preferences regarding depression among individuals with multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis.

Marrie RA, Walker JR, Graff LA, Patten SB, Bolton JM, Marriott JJ, Fisk JD, Hitchon C, Peschken C, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Immune-mediated Inflammatory Disease.

Patient Educ Couns. 2019 Apr 6. pii: S0738-3991(19)30132-6. doi: 10.1016/j.pec.2019.04.007. [Epub ahead of print]

12.

Comorbidity in multiple sclerosis: Past, present and future.

Marrie RA.

Clin Invest Med. 2019 Mar 23;42(1):E5-E12. doi: 10.25011/cim.v42i1.32383.

PMID:
30904030
13.

The Prevalence and Risk Factors of Undiagnosed Depression and Anxiety Disorders Among Patients With Inflammatory Bowel Disease.

Lewis K, Marrie RA, Bernstein CN, Graff LA, Patten SB, Sareen J, Fisk JD, Bolton JM; CIHR Team in Defining the Burden and Managing the Effects of Immune-Mediated Inflammatory Disease .

Inflamm Bowel Dis. 2019 Mar 19. pii: izz045. doi: 10.1093/ibd/izz045. [Epub ahead of print]

PMID:
30888037
14.

Ten-year trajectories of health care utilization by Manitobans with MS predict nursing home entry.

Finlayson M, Ekuma O, Finlayson G, Jiang D, Marrie RA.

Neurol Clin Pract. 2019 Feb;9(1):16-23. doi: 10.1212/CPJ.0000000000000553.

PMID:
30859003
15.

Traditional risk factors may not explain increased incidence of myocardial infarction in MS.

Marrie RA, Garland A, Schaffer SA, Fransoo R, Leung S, Yogendran M, Kingwell E, Tremlett H.

Neurology. 2019 Apr 2;92(14):e1624-e1633. doi: 10.1212/WNL.0000000000007251. Epub 2019 Mar 6.

PMID:
30842298
16.

Validation of an algorithm for identifying MS cases in administrative health claims datasets.

Culpepper WJ, Marrie RA, Langer-Gould A, Wallin MT, Campbell JD, Nelson LM, Kaye WE, Wagner L, Tremlett H, Chen LH, Leung S, Evans C, Yao S, LaRocca NG; United States Multiple Sclerosis Prevalence Workgroup (MSPWG).

Neurology. 2019 Mar 5;92(10):e1016-e1028. doi: 10.1212/WNL.0000000000007043. Epub 2019 Feb 15.

17.

The prevalence of MS in the United States: A population-based estimate using health claims data.

Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, Cutter GR, Kaye WE, Wagner L, Tremlett H, Buka SL, Dilokthornsakul P, Topol B, Chen LH, LaRocca NG; US Multiple Sclerosis Prevalence Workgroup.

Neurology. 2019 Mar 5;92(10):e1029-e1040. doi: 10.1212/WNL.0000000000007035. Epub 2019 Feb 15.

18.

A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS.

Nelson LM, Wallin MT, Marrie RA, Culpepper WJ, Langer-Gould A, Campbell J, Buka S, Tremlett H, Cutter G, Kaye W, Wagner L, Larocca NG; United States Multiple Sclerosis Prevalence Workgroup.

Neurology. 2019 Mar 5;92(10):469-480. doi: 10.1212/WNL.0000000000007044. Epub 2019 Feb 15. Review.

19.

Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis.

Mexhitaj I, Nyirenda MH, Li R, O'Mahony J, Rezk A, Rozenberg A, Moore CS, Johnson T, Sadovnick D, Collins DL, Arnold DL, Gran B, Yeh EA, Marrie RA, Banwell B, Bar-Or A.

Brain. 2019 Mar 1;142(3):617-632. doi: 10.1093/brain/awz017.

PMID:
30759186
20.

A surface-in gradient of thalamic damage evolves in pediatric multiple sclerosis.

Fadda G, Brown RA, Magliozzi R, Aubert-Broche B, O'Mahony J, Shinohara RT, Banwell B, Marrie RA, Yeh EA, Collins DL, Arnold DL, Bar-Or A; Canadian Pediatric Demyelinating Disease Network.

Ann Neurol. 2019 Mar;85(3):340-351. doi: 10.1002/ana.25429. Epub 2019 Feb 20.

21.

Prodrome in relapsing-remitting and primary progressive multiple sclerosis.

Wijnands JMA, Zhu F, Kingwell E, Zhao Y, Evans C, Fisk JD, Marrie RA, Tremlett H.

Eur J Neurol. 2019 Jul;26(7):1032-1036. doi: 10.1111/ene.13925. Epub 2019 Mar 1.

PMID:
30714270
22.

Accuracy of FRAX® in People With Multiple Sclerosis.

Bisson EJ, Finlayson ML, Ekuma O, Marrie RA, Leslie WD.

J Bone Miner Res. 2019 Jan 28:e3682. doi: 10.1002/jbmr.3682. [Epub ahead of print]

PMID:
30690793
23.

Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes.

Fitzgerald KC, Salter A, Tyry T, Fox RJ, Cutter G, Mowry EM, Marrie RA.

Mult Scler Relat Disord. 2019 Apr;29:86-93. doi: 10.1016/j.msard.2019.01.031. Epub 2019 Jan 24.

PMID:
30690340
24.

Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders.

Ciccarelli O, Cohen JA, Reingold SC, Weinshenker BG; International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.

Lancet Neurol. 2019 Feb;18(2):185-197. doi: 10.1016/S1474-4422(18)30460-5. Review.

PMID:
30663608
25.

Factors associated with receiving bone mineral density screening among people with multiple sclerosis.

Bisson EJ, Ekuma O, Marrie RA, Leslie WD, Finlayson ML.

Mult Scler Relat Disord. 2019 Feb;28:305-308. doi: 10.1016/j.msard.2019.01.022. Epub 2019 Jan 8.

PMID:
30641355
26.

Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders.

Whitehouse CE, Fisk JD, Bernstein CN, Berrigan LI, Bolton JM, Graff LA, Hitchon CA, Marriott JJ, Peschken CA, Sareen J, Walker JR, Stewart SH, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Neurology. 2019 Jan 11. pii: 10.1212/WNL.0000000000006854. doi: 10.1212/WNL.0000000000006854. [Epub ahead of print]

PMID:
30635487
27.

MRI utilization during the diagnostic and post-diagnostic phases in multiple sclerosis.

Wijnands JMA, Ekuma O, Kingwell E, Zhu F, Zhao Y, Fisk JD, Evans C, Tremlett H, Marrie RA.

Mult Scler Relat Disord. 2019 Feb;28:138-144. doi: 10.1016/j.msard.2018.12.030. Epub 2018 Dec 23.

PMID:
30594814
28.

Pseudobulbar affect: Prevalence and association with symptoms in multiple sclerosis.

Fitzgerald KC, Salter A, Tyry T, Fox RJ, Cutter G, Marrie RA.

Neurol Clin Pract. 2018 Dec;8(6):472-481. doi: 10.1212/CPJ.0000000000000523.

PMID:
30588376
29.

Pharmaceutical cannabinoid use in Manitoba, 2004/05 to 2014/15: a population-based cross-sectional study.

Alkabbani W, Marrie RA, Bugden S, Alessi-Severini S, Daeninck P, Bolton J, Sareen J, Leong C.

CMAJ Open. 2018 Dec 18;6(4):E637-E642. doi: 10.9778/cmajo.20180109. Print 2018 Oct-Dec.

30.

A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?

Forbes JD, Chen CY, Knox NC, Marrie RA, El-Gabalawy H, de Kievit T, Alfa M, Bernstein CN, Van Domselaar G.

Microbiome. 2018 Dec 13;6(1):221. doi: 10.1186/s40168-018-0603-4.

31.

Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study.

Setayeshgar S, Kingwell E, Zhu F, Zhang T, Carruthers R, Marrie RA, Evans C, Tremlett H.

Mult Scler Relat Disord. 2019 Jan;27:364-369. doi: 10.1016/j.msard.2018.11.004. Epub 2018 Nov 9.

PMID:
30476872
32.

Obesity and brain volume loss in multiple sclerosis.

Marrie RA, Butzkueven H, Ascherio A.

Neurology. 2018 Dec 11;91(24):1079-1080. doi: 10.1212/WNL.0000000000006638. Epub 2018 Nov 14. No abstract available.

PMID:
30429279
33.

Diabetes and anxiety adversely affect cognition in multiple sclerosis.

Marrie RA, Patel R, Figley CR, Kornelsen J, Bolton JM, Graff L, Mazerolle EL, Marriott JJ, Bernstein CN, Fisk JD; Comorbidity and Cognition in Multiple Sclerosis (CCOMS) Study Group.

Mult Scler Relat Disord. 2019 Jan;27:164-170. doi: 10.1016/j.msard.2018.10.018. Epub 2018 Oct 23.

34.

International consensus on quality standards for brain health-focused care in multiple sclerosis.

Hobart J, Bowen A, Pepper G, Crofts H, Eberhard L, Berger T, Boyko A, Boz C, Butzkueven H, Celius EG, Drulovic J, Flores J, Horáková D, Lebrun-Frénay C, Marrie RA, Overell J, Piehl F, Rasmussen PV, Sá MJ, Sîrbu CA, Skromne E, Torkildsen Ø, van Pesch V, Vollmer T, Zakaria M, Ziemssen T, Giovannoni G.

Mult Scler. 2018 Nov 1:1352458518809326. doi: 10.1177/1352458518809326. [Epub ahead of print]

PMID:
30381987
35.

Use of eHealth and mHealth technology by persons with multiple sclerosis.

Marrie RA, Leung S, Tyry T, Cutter GR, Fox R, Salter A.

Mult Scler Relat Disord. 2019 Jan;27:13-19. doi: 10.1016/j.msard.2018.09.036. Epub 2018 Oct 2.

PMID:
30296732
36.

Incidence and prevalence of MS in children: A population-based study in Ontario, Canada.

Marrie RA, O'Mahony J, Maxwell C, Ling V, Yeh EA, Arnold DL, Bar-Or A, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Neurology. 2018 Oct 23;91(17):e1579-e1590. doi: 10.1212/WNL.0000000000006395. Epub 2018 Sep 26.

PMID:
30258022
37.

Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review.

Gasim M, Bernstein CN, Graff LA, Patten SB, El-Gabalawy R, Sareen J, Bolton JM, Marriott JJ, Fisk JD, Marrie RA; CIHR team “Defining the burden and managing the effects of psychiatric comorbidity in chronic inflammatory disease”.

Mult Scler Relat Disord. 2018 Nov;26:124-156. doi: 10.1016/j.msard.2018.09.008. Epub 2018 Sep 12.

38.

Physical activity and dentate gyrus volume in pediatric acquired demyelinating syndromes.

Longoni G, Brown RA, Aubert-Broche B, Grover SA, Branson HM, Fetco D, Bar-Or A, Marrie RA, Motl RW, Collins DL, Narayanan S, Arnold DL, Banwell B, Yeh EA.

Neurol Neuroimmunol Neuroinflamm. 2018 Sep 6;5(6):e499. doi: 10.1212/NXI.0000000000000499. eCollection 2018 Nov.

39.

MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study.

Fadda G, Brown RA, Longoni G, Castro DA, O'Mahony J, Verhey LH, Branson HM, Waters P, Bar-Or A, Marrie RA, Yeh EA, Narayanan S, Arnold DL, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Lancet Child Adolesc Health. 2018 Mar;2(3):191-204. doi: 10.1016/S2352-4642(18)30026-9. Epub 2018 Feb 1.

PMID:
30169254
40.

Pediatric-onset multiple sclerosis is associated with reduced parental health-related quality of life and family functioning.

O'Mahony J, Marrie RA, Laporte A, Bar-Or A, Yeh EA, Brown A, Dilenge ME, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Mult Scler. 2018 Aug 30:1352458518796676. doi: 10.1177/1352458518796676. [Epub ahead of print]

PMID:
30160208
41.

Identifying optic neuritis and transverse myelitis using administrative data.

Marrie RA, Ekuma O, Wijnands JMA, Kingwell E, Zhu F, Zhao Y, Fisk JD, Evans C, Tremlett H.

Mult Scler Relat Disord. 2018 Oct;25:258-264. doi: 10.1016/j.msard.2018.08.013. Epub 2018 Aug 13.

PMID:
30144696
42.

Mining healthcare data for markers of the multiple sclerosis prodrome.

Högg T, Wijnands JMA, Kingwell E, Zhu F, Lu X, Evans C, Fisk JD, Marrie RA, Zhao Y, Tremlett H.

Mult Scler Relat Disord. 2018 Oct;25:232-240. doi: 10.1016/j.msard.2018.08.007. Epub 2018 Aug 8.

PMID:
30121490
43.

Identifying priority outcomes that influence selection of disease-modifying therapies in MS.

Day GS, Rae-Grant A, Armstrong MJ, Pringsheim T, Cofield SS, Marrie RA.

Neurol Clin Pract. 2018 Jun;8(3):179-185. doi: 10.1212/CPJ.0000000000000449.

44.

Factors associated with perceived need for mental health care in multiple sclerosis.

Orr J, Bernstein CN, Graff LA, Patten SB, Bolton JM, Sareen J, Marriott JJ, Fisk JD, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Immune-mediated Inflammatory Disease.

Mult Scler Relat Disord. 2018 Oct;25:179-185. doi: 10.1016/j.msard.2018.07.043. Epub 2018 Jul 29.

45.

Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years.

Setayeshgar S, Kingwell E, Zhu F, Zhang X, Zhang T, Marrie RA, Carruthers R, Tremlett H.

Mult Scler Relat Disord. 2018 Oct;25:57-60. doi: 10.1016/j.msard.2018.07.012. Epub 2018 Jul 9.

PMID:
30036855
46.

Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis.

Kowalec K, Wright GEB, Drögemöller BI, Aminkeng F, Bhavsar AP, Kingwell E, Yoshida EM, Traboulsee A, Marrie RA, Kremenchutzky M, Campbell TL, Duquette P, Chalasani N, Wadelius M, Hallberg P, Xia Z, De Jager PL, Denny JC, Davis MF, Ross CJD, Tremlett H, Carleton BC.

Nat Genet. 2018 Aug;50(8):1081-1085. doi: 10.1038/s41588-018-0168-y. Epub 2018 Jul 16.

47.

Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease.

Bernstein CN, Hitchon CA, Walld R, Bolton JM, Sareen J, Walker JR, Graff LA, Patten SB, Singer A, Lix LM, El-Gabalawy R, Katz A, Fisk JD, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Inflamm Bowel Dis. 2019 Jan 10;25(2):360-368. doi: 10.1093/ibd/izy235.

PMID:
29986021
48.

Five years before multiple sclerosis onset: Phenotyping the prodrome.

Wijnands JM, Zhu F, Kingwell E, Zhao Y, Ekuma O, Lu X, Evans C, Fisk JD, Marrie RA, Tremlett H.

Mult Scler. 2019 Jul;25(8):1092-1101. doi: 10.1177/1352458518783662. Epub 2018 Jul 6.

PMID:
29979093
49.

Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases.

Marrie RA, Walld R, Bolton JM, Sareen J, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Gen Hosp Psychiatry. 2018 Jul - Aug;53:65-72. doi: 10.1016/j.genhosppsych.2018.06.001. Epub 2018 Jun 7.

50.

Registry Cohort Study to Determine Risk for Multiple Sclerosis after Vaccination for Pandemic Influenza A(H1N1) with Arepanrix, Manitoba, Canada.

Mahmud SM, Bozat-Emre S, Mostaço-Guidolin LC, Marrie RA.

Emerg Infect Dis. 2018 Jul;24(7):1267-1274. doi: 10.3201/eid2407.161783.

Supplemental Content

Loading ...
Support Center